Search Results
Your search for ,WHo matches 20675 pages
Showing 8251 - 8300Should Restrictions on Genetic Testing Be Loosened?
The loosening of restrictions on genetic testing would mean that all health-care providers could help move this needle to where it should be, according to Kevin S. Hughes, MD, a surgeon at Massachusetts General Hospital, Professor of Surgery at Harvard Medical School, and Medical Director of the...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Expert Point of View: Tanguy Y. Seiwert, MD
Moderator of the session, Tanguy Y. Seiwert, MD, Director of the Head and Neck Cancer Oncology Disease Group and Assistant Professor of Oncology at Johns Hopkins University, in Baltimore, underscored the “dramatically good” preclinical data supporting the use of mTOR inhibitors in advanced...
Study Suggests Adjuvant Everolimus May Benefit Patients With Advanced Head and Neck Cancer
The mTOR inhibitor everolimus, used to treat breast and kidney cancers, may benefit patients with advanced squamous cell carcinoma of the head and neck, according to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.1 The results of an investigator-initiated, phase II...
ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer
ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer.1 “Around the world, there is a huge variation in resources, and what is available to clinicians may change week to week,” said Mary D....
Immunotherapy ‘Comes of Age’ in Breast Cancer
Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens, and expansion into different disease subtypes should become part of this emerging landscape, according to Hope S. Rugo, MD, FASCO, Professor of Medicine...
T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...
New Prognostic Score for Asymptomatic Patients With Early-Stage CLL
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
Factors Associated With Early Readmissions to Hospital Oncology Services
In a study reported in JCO Oncology Practice, Zibelli et al found that patients with cancer readmitted to hospital within 30 days from index admission often made the decision to return to hospital themselves, without input from their care teams. Study Details The study included 33 patients...
Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers
Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...
Pediatric Cancer Investment Needs and Benefits: Findings From a Commission Created by The Lancet Oncology
Improving care for children with cancer worldwide could bring a triple return on investment and prevent millions of deaths, according to a new Commission report published by Atun et al in The Lancet Oncology. Without additional investment in childhood cancer care, new estimates produced for the...
Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial
In a phase II trial reported in JAMA Oncology, Phillips et al found that stereotactic ablative radiotherapy (SABR) was associated with improved outcomes vs observation in men with oligometastatic prostate cancer. The benefit was augmented in patients with total consolidation of disease identified...
Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab
A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...
$20 Million in Grants Awarded to Identify Therapies for COVID-19
The partners in the COVID-19 Therapeutics Accelerator—a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard—awarded $20 million in initial grants to three institutions. The University of Washington, the University of Oxford, and La Jolla Institute...
Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction
Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...
Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing
Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...
KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial
In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous...
Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19
In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...
Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer
An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...
Second-Line Lurbinectedin in Small Cell Lung Cancer
As reported in The Lancet Oncology by Trigo et al, second-line treatment with the selective oncogenic transcription inhibitor lurbinectedin showed activity in patients with small cell lung cancer included in a phase II basket trial. The trial includes cohorts representing nine different tumor...
AACR Annual Meeting 2020 to Be Held in a Virtual-Only Format
Today, the American Association for Cancer Research (AACR) Board of Directors issued the following announcement: The AACR has been closely monitoring the rapid escalation of the COVID-19 pandemic. The health and safety of all Annual Meeting attendees and the patients and communities they serve are...
FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes
On April 3, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia that fails to respond to an erythropoiesis-stimulating agent and requires two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk...
Harvard Medical Student’s Innovation: Disinfection You Can See
In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...
FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations
The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...
Apixaban for Cancer-Associated Venous Thromboembolism
For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...
Cancer Care in the Time of COVID-19: Statement From Fox Chase Cancer Center
In an article published by Kutikov et al in Annals of Internal Medicine, practitioners from Fox Chase Cancer Center reviewed the challenges faced in cancer care during the COVID-19 crisis and suggested measures that may help to maintain standards of care while reducing risk of transmission as well...
Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD
During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...
ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19
On April 1, the ASH Research Collaborative's (ASH RC) Data Hub launched the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy, a global registry with clinical data exclusively on people with COVID-19 and a current or past diagnosis of a hematologic malignancy. The registry is intended to ...
Factors Associated With Small Adult Height in Childhood Cancer Survivors
In an analysis from the French Childhood Cancer Survivors (CCS) Study reported in the Journal of Clinical Oncology, Demoor-Goldschmidt et al found that receipt of pituitary irradiation, busulfan, and higher doses of lomustine were risk factors for small adult height in survivors of childhood...
Maintaining Blood Donations During the COVID-19 Pandemic
A major casualty of the coronavirus disease 2019 (COVID-19) pandemic is the dramatic decrease in the number of blood donations across the United States. As more people are urged to shelter-in-place and avoid social contact, the number of cancellations in blood drives has been dramatic. According to ...
Gynecologic Cancer Screening After a Natural Disaster
Cervical cancer screening rates were significantly affected in the years following the Great East Japan Earthquake of 2011, according to a report published by Miki et al in PLOS ONE. “Conflicts and disasters, and the social isolation that often follows, have a major impact on health care and lead...
Disparities in Receipt of Chemotherapy Among Patients With pN1 Lung Cancer
In patients with non–small cell lung cancer (NSCLC) where the cancer has spread to one or more lymph nodes close to the lungs—a condition known as pathologic N1 (pN1) disease—current guidelines recommend a two-part protocol: surgical resection, followed by chemotherapy. However, a retrospective...
Effect of Familial and Hereditary Cancer Syndromes on Risk of Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Jennifer L. Beebe-Dimmer, MPH, PhD, and colleagues found that risk of prostate cancer varied according to cancer family history, with the strongest association being observed between family history and early-onset prostate cancer. Study...
COVID-19 and Pediatric Patients With Cancer
In a correspondence published in The Lancet Oncology, Rishi S. Kotecha, MB, ChB, of the Government of Western Australia Department of Health, identified challenges in protecting children with cancer from COVID-19 infection and stressed that some measures proposed to protect adults with cancer may...
Bispecific Antibodies: Successes and Challenges
Bispecific T-cell engager (BiTE) antibodies, such blinatumomab, may be the most appealing type of bispecific antibodies, a class of manufactured constructs that is expected to expand into the solid tumor space, according to Hermann Einsele, MD, Professor of Medicine at the University of Würzburg,...
Selumetinib for Inoperable Plexiform Neurofibromas in Children With Neurofibromatosis Type 1
In a phase II trial reported in The New England Journal of Medicine, Gross et al found that the oral MEK inhibitor selumetinib produced a high response rate and durable responses in children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas. Study Details The study,...
Does Pembrolizumab Show Activity in Some Rare Cancers?
A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers. “Our findings that pembrolizumab has a favorable toxicity...
French Guidelines on Patients With Cancer and SARS-CoV-2 Infection
As reported by You et al in The Lancet Oncology, a representative group of French medical and radiation oncologists formulated guidelines to protect patients with cancer against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Guideline development was overseen by the French...
Cancer Care Amid the COVID-19 Pandemic
To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy...
The Blind Leading the Blind: COVID-19, Cancer, and the Need for More Data
In the novel Blindness, Portuguese author José Saramago describes an epidemic that quickly and inexorably causes nearly all inhabitants of an unnamed city to lose their sight. The Nobel Laureate writes in long uninterrupted sentences, making the reader experience the fears and anxieties of the...
American College of Surgeons Issues COVID-19 Guidelines for Triage of Patients Undergoing Cancer Surgery
This week, the American College of Surgeons issued guidelines on triage of patients undergoing elective cancer surgery during the COVID-19 pandemic. During the current COVID-19 pandemic, hospital leadership and individual providers are facing increasingly difficult decisions about how to conserve...
First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors
In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or KRAS/NRAS mutations. Study Details The study, conducted in Australia and New...
End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The Lancet Oncology by Sandra M. Swain, MD, and colleagues, long-term follow-up of the phase III CLEOPATRA trial has shown maintained overall survival benefit with the addition of pertuzumab to trastuzumab plus docetaxel in patients with previously untreated HER2-positive metastatic...
Practicing Oncology in the Era of COVID-19
The coronavirus-related pandemic has affected nearly every corner of the globe. What originated in one country is on course to likely affect every country in the world. In a few countries, the disease has peaked and is on the downward trend. In some, including the United States, the disease is on...
Predicting Which Patients With Ovarian Cancer May Respond to Combination PARP and PD-1 Inhibition
In some patients with advanced ovarian cancer, the combination of programmed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors can produce responses, but up until now, investigators have been unable to predict which patients would not benefit from the treatment and...
Pemigatinib for Previously Treated Advanced Cholangiocarcinoma
In the phase II FIGHT-202 study reported in The Lancet Oncology, Ghassan K. Abou-Alfa, MD, and colleagues found that the fibroblast growth factor receptor 1 (FGFR1), FGFR2, and FGFR3 inhibitor pemigatinib was active in patients with previously treated locally advanced or metastatic...
Leaving ‘No Stone Unturned’ in Research to Cure a Rare Kidney Cancer
It is devasting for a doctor to tell a patient there is nothing that can be done to help him. For Nizar Tannir, MD, FACP, the words of a young father still ring in his ears: “I was trying to tell him that, unfortunately, despite all our efforts, I didn’t have any more treatments to offer him. And...
New Study in JCO Oncology Practice Highlights Smoking Cessation Initiative Success for Patients With Cancer
A new study in JCO Oncology Practice (JCO OP) highlights an effective effort to increase the use of evidence-based state smoking cessation programs among patients with cancer and survivors who use tobacco. In Michigan, state agencies and the Michigan Oncology Quality Consortium partnered to create...
Survey Says: A Low-Tech Approach Leads to High-Quality Care in South Africa
An American medical student travels to rural Uganda; there, he finds most villagers walking miles to receive health care at the nearby district hospital. Upon arrival, they spend hours waiting in line. Some patients make this trip monthly. Before entering internal medicine residency, Daniel O’Neil, ...
ASCO, Project ECHO Partner to Pilot Impactful Cancer Tele-Education Program in Nepal
Cancer care for patients in rural areas is challenging—for example, in the United States, only 3% of medical oncologists practice in rural areas, and patients must travel long distances to see specialists. Patients may also have trouble managing complications from care or follow-up from treatment....
